Australia's Mesoblast rises on FDA approval for new potency assay for commercial Ryoncil
24/09/2026 01:38
BUZZ-Australia's Mesoblast rises on FDA approval for new potency assay for commercial Ryoncil ** Shares of Mesoblast MSB.AX rise as much as 5.1% to A$2.29, their biggest intraday pct gain since August 28
** Shares hit their highest level since September 9
** The biotech company gets US FDA approval to implement new potency assay for release and stability monitoring of all new commercial products of Ryoncil, its mesenchymal stromal cell product
** Ryoncil is for the treatment of steroid-refractory acute graft versus host disease
** YTD, Mesoblast stock down 17.7%
(Reporting by Nichiket Sunil in Bengaluru)
Recent news on Mesoblast
See all newsBrief: Mesoblast William Burns To Retire From Board At 2026 AGM
Brief: Mesoblast Says Q1 Net Revenues Up 44%
Australia's Mesoblast hits one-month high on upbeat quarterly update
Australia's Mesoblast drops as Bell Potter cuts target price after key drug misses sales view
Brief: Mesoblast Says FDA Approves New Potency Assay For Commercial Ryoncil